Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens

BACKGROUND: NanoString’s Prosigna™ Breast Cancer Prognostic Gene Signature Assay is based on the PAM50 gene expression signature. The test outputs a risk of recurrence (ROR) score, risk category, and intrinsic subtype (Luminal A/B, HER2-enriched, Basal-like). The studies described here were designed...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Nielsen, Torsten, Wallden, Brett, Schaper, Carl, Ferree, Sean, Liu, Shuzhen, Gao, Dongxia, Barry, Garrett, Dowidar, Naeem, Maysuria, Malini, Storhoff, James
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2014
Gaiak:
Technical Advance
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4008304/
https://ncbi.nlm.nih.gov/pubmed/24625003
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-14-177
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak